A clinical-stage biotech developing next-generation medicines for retinal diseases that cause blindness, aiming for longer-lasting anti-VEGF eye injections with candidates like Zenkuda (tarcocimab tedromer) and the bispecific KSI-501. Founded in 2009 as Oligasis and renamed Kodiak Sciences in 2015, the company takes its name from Alaska's mighty Kodiak bear — and fittingly, its Swiss manufacturing plant is called "Ursus," the Latin word for bear.
Perlroth VictorChairman and CEO, Director · 2 transactions
-30.5%
2.40M
300.0K
—
—
Borgeson John A.Chief Financial Officer · 15 transactions
+21.3%
216.0K
99.0K
—
65.2K
Select a row to see that insider’s individual transactions. † Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: +2.54M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.